Phase I study of safety, pharmacokinetics, and efficacy of TSU-68 plus S-1 combination in patients with advanced hepatocellular carcinoma

被引：0
|
作者：
Ikeda, Masafumi
Shiina, Shuichiro
Nakachi, Kohei
Mitsunaga, Shuichi
Shimizu, Satoshi
Kojima, Yasushi
Ueno, Hideki
Morizane, Chigusa
Kondo, Shunsuke
Sakamoto, Yasunari
Tateishi, Ryosuke
Asaoka, Yoshinari
Koike, Kazuhiko
Arioka, Hitoshi
Okusaka, Takuji
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Univ Tokyo, Tokyo, Japan
[3] Natl Ctr Global Hlth & Med, Tokyo, Japan
[4] Natl Canc Ctr, Tokyo, Japan
[5] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan
[6] Yokohama Rosai Hosp, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.262
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
262
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
    Ikeda, Masafumi
    Shiina, Shuichiro
    Nakachi, Kohei
    Mitsunaga, Shuichi
    Shimizu, Satoshi
    Kojima, Yasushi
    Ueno, Hideki
    Morizane, Chigusa
    Kondo, Shunsuke
    Sakamoto, Yasunari
    Asaoka, Yoshinari
    Tateishi, Ryosuke
    Koike, Kazuhiko
    Arioka, Hitoshi
    Okusaka, Takuji
    [J]. INVESTIGATIONAL NEW DRUGS, 2014, 32 (05) : 928 - 936
  • [2] Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
    Masafumi Ikeda
    Shuichiro Shiina
    Kohei Nakachi
    Shuichi Mitsunaga
    Satoshi Shimizu
    Yasushi Kojima
    Hideki Ueno
    Chigusa Morizane
    Shunsuke Kondo
    Yasunari Sakamoto
    Yoshinari Asaoka
    Ryosuke Tateishi
    Kazuhiko Koike
    Hitoshi Arioka
    Takuji Okusaka
    [J]. Investigational New Drugs, 2014, 32 : 928 - 936
  • [3] Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma
    Furuse, Junji
    Okusaka, Takuji
    Kaneko, Shuichi
    Kudo, Masatoshi
    Nakachi, Kohei
    Ueno, Hideki
    Yamashita, Tatsuya
    Ueshima, Kazuomi
    [J]. CANCER SCIENCE, 2010, 101 (12) : 2606 - 2611
  • [4] Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
    Koizumi, W.
    Yamaguchi, K.
    Hosaka, H.
    Takinishi, Y.
    Nakayama, N.
    Hara, T.
    Muro, K.
    Baba, H.
    Sasaki, Y.
    Nishina, T.
    Fuse, N.
    Esaki, T.
    Takagi, M.
    Gotoh, M.
    Sasaki, T.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (08) : 2079 - 2086
  • [5] Randomized phase II study of S-1/CDDP plus TSU-68 versus S-1/CDDP in patients with advanced gastric cancer
    Yamaguchi, Kensei
    Koizumi, Wasaburo
    Hosaka, Hisashi
    Takinishi, Yasutaka
    Nakayama, Norisuke
    Hara, Takuo
    Muro, Kei
    Baba, Hideo
    Sasaki, Yasutsuna
    Nishina, Tomohiro
    Fuse, Nozomu
    Esaki, Taito
    Takagi, Masakazu
    Gotoh, Masahiro
    Kitamura, Ryuichi
    Matsumoto, Hideki
    Sasaki, Tsuneo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
    W Koizumi
    K Yamaguchi
    H Hosaka
    Y Takinishi
    N Nakayama
    T Hara
    K Muro
    H Baba
    Y Sasaki
    T Nishina
    N Fuse
    T Esaki
    M Takagi
    M Gotoh
    T Sasaki
    [J]. British Journal of Cancer, 2013, 109 : 2079 - 2086
  • [7] Erratum: Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
    W Koizumi
    K Yamaguchi
    H Hosaka
    Y Takinishi
    N Nakayama
    T Hara
    K Muro
    H Baba
    Y Sasaki
    T Nishina
    N Fuse
    T Esaki
    M Takagi
    M Gotoh
    T Sasaki
    [J]. British Journal of Cancer, 2014, 111 : 2382 - 2382
  • [8] A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Yoshida, Haruhiko
    Tateishi, Ryosuke
    Sato, Shinpei
    Kawabe, Takao
    Obi, Shuntaro
    Kondo, Yuji
    Taniguchi, Makoto
    Tagawa, Kazumi
    Ikeda, Masafumi
    Morizane, Chigusa
    Okusaka, Takuji
    Arioka, Hitoshi
    Shiina, Shuichiro
    Omata, Masao
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 315 - 324
  • [9] A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Haruhiko Yoshida
    Ryosuke Tateishi
    Shinpei Sato
    Takao Kawabe
    Shuntaro Obi
    Yuji Kondo
    Makoto Taniguchi
    Kazumi Tagawa
    Masafumi Ikeda
    Chigusa Morizane
    Takuji Okusaka
    Hitoshi Arioka
    Shuichiro Shiina
    Masao Omata
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 67 : 315 - 324
  • [10] A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation
    Inaba, Yoshitaka
    Kanai, Fumihiko
    Aramaki, Takeshi
    Yamamoto, Takanobu
    Tanaka, Toshihiro
    Yamakado, Koichiro
    Kaneko, Shuichi
    Kudo, Masatoshi
    Imanaka, Kazuho
    Kora, Shinichi
    Nishida, Norifumi
    Kawai, Nobuyuki
    Seki, Hiroshi
    Matsui, Osamu
    Arioka, Hitoshi
    Arai, Yasuaki
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2832 - 2840
12345